Trial Profile

A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talazoparib (Primary) ; ZEN 3694 (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms TNBC
Sponsors Newsoara Biopharma; Zenith Epigenetics

Most Recent Events

01 May 2024 Status changed from active, no longer recruiting to discontinued. Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.
06 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
06 Feb 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com